CTRI/2023/02/049470已完成3 期
A double blind, randomized, crossover, two period, parallel group, single center, placebocontrolled study to evaluate safety and efficacy of WSCS IIIM (comprising extract A andExtract B) for sleep disorder(s) in otherwise healthy volunteers
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 入组人数
- 40
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •1. Male volunteers who are 18 or older to 72 years.
- •2. Insomnia Severity Index 10-14
- •3. Meet diagnostic criteria for Insomnia Disorder per DSM-5
- •4. Willing and able to sign Informed consent form
- •5. Not planning on moving away from the area for the subsequent 12 weeks
- •6.Subjects should not have Milk during the study
排除标准
- •1. Night shift workers and individuals who nap 3 or more times per week over the preceding month
- •2. Consumption of caffeine beverages tea, coffee, or cola comprising usually more than 5 cups or glasses per day
- •3. Participation in another trial for insomnia
- •4. Subjects having milk on regular basis.
- •5. Persons who are unable to participate for the entire duration of the study, or in the opinion of the investigators, are likely to be noncompliant with the obligations inherent in the trial participation
- •6. Persons self describing with severe anxiety or severe depression BDI score of 29 or higher or severe anxiety BAI score of 36 or higher
- •7. Persons with a history of epilepsy, seizures, or dementia any significant,
- •severe or unstable, acute progressive medical or surgical condition stroke or head injury
- •8. Current alcohol or substance abuse/dependence must have greater than90 days of sobriety
- •9. Presence of other neurological disorders Ex multiple sclerosis, Parkinsons Disease
- •10. Presence of an untreated or unstable medical or psychiatric comorbid condition ex major depressive disorder or psychotic disorder requiring admission within the last two years People using psychotropic medication hypnotic or sedative medications may be included if they are on a stable dosage for the last 2 months prior to the study, if the dose remains stable throughout the study, and if the medication is judged to not interfere with the study outcomes.
- •11. Currently on medications known to produce insomnia ex
研究者
相似试验
进行中（未招募）
1 期
A trial investigating liraglutide on the liver glucose production during induced hypoglycaemic in type 1 diabetes mellitussubjectsEUCTR2014-001381-96-ATMedizinische Universität Graz / Endokrinologie und Stoffwechsel
进行中（未招募）
不适用
A randomized, double-blind, two way cross-over, proof of concept study to compare the efficacy, safety, pharmacokinetics and pharmacodynamics of two-week oral administration of QAV680 versus placebo, with an extended open-label inhaled corticosteroid period, in steroid-free, mild to moderate persistent asthma patientsEUCTR2008-005168-15-DEovartis Pharma Services AG50
已完成
2 期
Safety , Pharmacokinetics and efficacy of QAV680 in asthma patientsCTRI/2009/091/000282ovartis Healthcare Pvt Ltd50
进行中（未招募）
不适用
A double-blind, randomized, 2-way cross-over, phase II, efficacy trial in cancer patients to assess the overall efficacy, patient preference, morphine related side effect profile and safety of the Egalet® controlled release morphine formulation 30-240 mg once daily compared to MST Continus® 15-120 mg twice daily after 2 weeks of treatmentcancer patientsMedDRA version: 8.1Level: LLTClassification code 10058019Term: Cancer painEUCTR2006-006579-19-LTEgalet a/s60
进行中（未招募）
不适用
Randomised, double-blind, double-dummy, cross-over trial comparing salmeterol 50 µg b.i.d. via a novel DPI versus salmeterol 50 µg b.i.d. via Diskus in adult patients with persistent asthma - Inhalation Study Salmeterol DPIAdult patients with stable persistent asthmaMedDRA version: 9.1Level: LLTClassification code 10049106Term: Asthma chronicEUCTR2006-006793-26-DEmibe GmbH Arzneimittel